

Angola
Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Angola		
2. Grant number: 17-AGO-18d-X / 17-AGO-08I-Y		
3. Date of Decision Letter: 07 June 2017		
4. Date of the Partnership Framework Agreement: 04 October 2013		
5. Programme title: NVS, Measles-Rubella Catch-up Campaign¹		
6. Vaccine type: Measles rubella		
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 doses per vial, LYOPHILISED		
8. Programme duration²: 2017		
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)		
	2017	Total³
Programme Budget (US\$)	US\$4,554,500	US\$4,554,500
10. Vaccine introduction grant (in US\$): 1,117,500. Payable up to six months before vaccine introduction.		
11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴		
Type of supplies to be purchased with Gavi funds in each year	2017	
Number of Measles-Rubella vaccines doses	7,251,900	
Annual Amounts (US\$)	US\$4,554,500	
12. Procurement agency: UNICEF		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		
15. Operational support for campaigns: Not applicable		

¹ Exceptional catalytic support

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

16. Additional reporting requirements:	
Reports and other information :	Due dates
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
Supplementary Immunisation Activity (SIA) technical report	Within 3 months of end of campaign
Post campaign coverage survey report	As soon as available
17. Financial clarifications: Not applicable	
18. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance:	
<ul style="list-style-type: none"> • 100% of the operational costs of the campaign; • 100% of the measles rubella vaccines to be used in routine immunisation. • 50% of the catch-up campaign doses (bundled vaccine, including AD syringes, reconstitution syringes and safety boxes) 	

On behalf of Gavi

Signed by



Hind Khatib-Othman
Managing Director, Country Programmes
07 June 2017